研究设计与统计

订阅

MedSci主页 / 所有栏目 / 研究设计与统计

病例对照研究中，如果病例组的结果对照组也有，在讨论中要怎么说？

2021-08-05 网络 网络

投稿病例对照研究
关注

病例对照研究中，如果病例组的结果对照组也有，在讨论中要怎么说-11.

《梅斯直播课：主编和审稿人在线教学：那些简单又有效的投稿秘诀》

回答问题11：病例对照研究中，如果病例组的结果对照组也有，在讨论中要怎么说

 

欢迎点赞、评论、分享

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775573, encodeId=dd891e755738c, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 03 09:52:34 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046208, encodeId=be8c204620861, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Fri Dec 03 06:52:34 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756177, encodeId=ead61e5617714, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sat Feb 19 10:52:34 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984146, encodeId=5d3e198414663, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Feb 02 09:52:34 CST 2022, time=2022-02-02, status=1, ipAttribution=)]
    2022-01-03 amyloid

    #对照#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1775573, encodeId=dd891e755738c, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 03 09:52:34 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046208, encodeId=be8c204620861, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Fri Dec 03 06:52:34 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756177, encodeId=ead61e5617714, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sat Feb 19 10:52:34 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984146, encodeId=5d3e198414663, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Feb 02 09:52:34 CST 2022, time=2022-02-02, status=1, ipAttribution=)]
    2021-12-03 ay2000fy

    #对照组#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1775573, encodeId=dd891e755738c, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 03 09:52:34 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046208, encodeId=be8c204620861, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Fri Dec 03 06:52:34 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756177, encodeId=ead61e5617714, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sat Feb 19 10:52:34 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984146, encodeId=5d3e198414663, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Feb 02 09:52:34 CST 2022, time=2022-02-02, status=1, ipAttribution=)]
    2022-02-19 xugc

    #病例对照#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1775573, encodeId=dd891e755738c, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 03 09:52:34 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046208, encodeId=be8c204620861, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Fri Dec 03 06:52:34 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756177, encodeId=ead61e5617714, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sat Feb 19 10:52:34 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984146, encodeId=5d3e198414663, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Feb 02 09:52:34 CST 2022, time=2022-02-02, status=1, ipAttribution=)]
    2022-02-02 fengyi812

    #病例对照研究#

    0

相关资讯

专访Catherine Otto—从BMJ子刊Heart主编的角度看文章发表

Heart接受发表的文章在全球总投稿中只占12%，如何使你的文章脱颖而出？听主编Catherine Otto为你支招。图：梅斯小编与Catherine Otto教授关于Catherine M. Otto教授Catherine M. Otto，是BMJ子刊Heart的主编，同时也是华盛顿大学医学中心心血管疾病部的心血管疾病训练项目的主任。作为一位超声心动图专家，她撰写了《Practice of

同等条件下，是不是外国专家对中国的稿件不太友好？

同等条件下，是不是外国专家对中国的稿件不太友好-6.

一份对中国学者友善的SCI名单，投稿需收藏

SCI影响因子更新在即，热门期刊MedSci指数先行来袭

投稿被秒拒是因为什么？语言？查重？主编会看图表吗？

一般秒拒是因为什么？语言？查重？主编会看图表吗？7.

怎么催编辑回复审稿人意见？

如果文章投出去，很久没返回意见，请问怎么催编辑回复审稿人意见-8.

收到拒稿意见怎么办？

收到拒稿意见怎么办？

拓展阅读

Haemophilia：血友病髌骨股骨关节形态学分析——病例对照研究

血友病关节病的形态学改变包括髌骨变小和中间倾斜，外侧髁和经髁轴变窄，并伴有髁间深度减小。这些改变必须牢记，尤其是在关节置换术前和术中评估时

医生登顶前列腺癌总体风险相关职业排行！从业满10年，风险翻两翻！

J Occup Med Toxicol ：职业与前列腺癌风险:前列腺癌流行病学研究结果(EPICAP)

样本量计算：成组设计的病例对照研究

样本量的计算直接影响着临床试验的阴性或者阳性，而如何计算样本量实现效益与经济的平衡，是非常关键的问题。本公众号将持续转载报道医咖会整理的样本量计算系列推文，以便掌握样本量计算方法，助力临床试验设计

Stroke：贫血是脑静脉血栓的危险因素？

Stroke：贫血是脑静脉血栓的危险因素？贫血 病例对照研究 危险因素背景和目的：贫血是脑静脉血栓（CVT）的危险因素，但是这个假设主要是依据病例报告。我们调查对照研究中，贫血和CVT的关系。方法：非匹配病例对照研究：选取单中心，前瞻性数据库中2006年7月到2014年12月间CVT患者。对照组选取静脉血栓危险因素的多环境和基因评估（MEGA）研究。根据世界卫生组织的标准诊断贫血：非哺乳期妇女的血

Neurology：卒中前应用抗血小板药与首次缺血性卒中

研究目的：为了调查卒中前抗血小板药物(PA)的使用是否与首次卒中的严重程度相关。研究方法：这是一项回顾性的病例对照研究，研究基于的数据来自一所前瞻地进行数据收集、基于医院的卒中注册中心。包括在内的共有3025名被认定首次缺血性卒中发作、症状出现5天内的患者。卒中严重程度通过美国国立卫生研究院卒中量表(NIHSS)进行测量。确诊时NIHSS 分数 ≤4的被归类为轻度卒中。PA组患者与非PA组患者通过

病例-对照研究特点及对照选择

在众多研究方法中，流行病学家从病例对照的研究设计中获益最多,研究大量的多种多样的联系。 病例对照研究与其他研究设计相比，耗用的时间、金钱和精力都明显较少，但同样能产生重要的科学发现。例如，早期关于艾滋病病因的研究中，病例对照研究体现了其优越性。病例对照研究明确了艾滋病的高危人群(如男同性恋者、静脉毒品使用者，以及接受输血的病人等)和危险因素(如多个性伴、男同性恋中缸交接受者，以及不